Safety under the regulatory spotlight — 181 documents in 90 days

101 documents in the last 30 days alone

This concentration of activity around safety may indicate a tightening cycle rather than a loosening one, because a large share of recent publications in a short window often suggests regulators are prioritizing risk surveillance, signal management, and post-market scrutiny. Sponsors should consider watching for shifts in labeling expectations, pharmacovigilance emphasis, and any new safety-related guidance that could raise the bar for evidence generation or faster issue escalation, as this could suggest a more active enforcement and review posture.